Susquehanna International Group’s Quoin Pharmaceuticals QNRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-320
Closed -$2.57K 13527
2025
Q1
$2.57K Buy
+320
New +$4.21K ﹤0.01% 12295
2024
Q3
Sell
-441
Closed -$8.97K 12831
2024
Q2
$8.97K Buy
+441
New +$11.2K ﹤0.01% 11785
2024
Q1
Sell
-599
Closed -$100K 13122
2023
Q4
$100K Buy
+599
New +$92.1K ﹤0.01% 11328
2023
Q3
Sell
-95
Closed -$19.7K 12785
2023
Q2
$19.7K Buy
+95
New +$19.6K ﹤0.01% 11640
2023
Q1
Sell
-52
Closed -$31.1K 13310
2022
Q4
$31.1K Buy
52
+15
+41% +$11.3K ﹤0.01% 11609
2022
Q3
$34K Buy
+37
New +$76.1K ﹤0.01% 12410
2019
Q4
Sell
-1
Closed -$44K 10443
2019
Q3
$44K Hold
1
﹤0.01% 9811
2019
Q2
$50K Hold
1
﹤0.01% 9841
2019
Q1
$78K Buy
+1
New +$179K ﹤0.01% 8343
2018
Q4
Hold
0
8510
2018
Q3
Sell
-1
Closed -$602K 8157
2018
Q2
$439K Hold
1
﹤0.01% 7054
2018
Q1
$434K Buy
+1
New +$826K ﹤0.01% 6919
2017
Q4
Hold
0
8739
2017
Q3
Hold
0
8358

Other funds holding QNRX

Susquehanna International Group's QNRX Position: Q2 2025 in Review

Susquehanna International Group sold out of Quoin Pharmaceuticals (QNRX) in Q2 2025, closing a stake of 320 shares — an estimated $2.57K sold.

Susquehanna International Group first reported a position in QNRX in Q1 2018 and held it in 11 quarters. The position peaked at $439K in Q2 2018. 7 funds tracked by Wall St. Rank hold QNRX as of Q2 2025.

  • Susquehanna International Group reported no remaining Quoin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Susquehanna International Group sold 320 Quoin Pharmaceuticals shares in Q2 2025, an estimated $2.57K.
  • Susquehanna International Group first reported a position in Quoin Pharmaceuticals in Q1 2018 and held it in 11 quarters.
  • Susquehanna International Group's Quoin Pharmaceuticals position peaked at $439K in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.